Girona Heart Registry

<

Epidemiology and Public Health Programme

Group Leader

Jaume Marrugat de la Iglesia

The mission of the Girona Heart Registry Research Group is to increase our knowledge of the magnitude of the populational problem of cardiovascular diseases, their molecular, cellular, and environmental mechanisms, and to design the best strategies for preventing them.

The ultimate goal for this knowledge is to significantly reduce this disease’s burden on society, creating tools (such as cardiovascular risk funcions) that allow us to transfer the knowledge we acquire to clinical practice.

The REGICOR Group also has the mission of training new researchers in this area of knowledge, and has been accredited with the Recognition for Advanced Research by the Catalan Government every two years since 1996.

The REGICOR project is well known for having recruited some 11,000 participants in population surveys and over 3,000 consecutive acute myocardial infarction (AMI) patients and for having compiled a biobank of DNA and plasma samples between 1995 and 2005 in Girona. The first-ever description of AMI incidence among the population in Spain was published by the REGICOR team.

The cardiovascular research project of the REGICOR has yielded over 500 international scientific publications. The REGICOR team has extensive experience in leading collaborative research at the international level. REGICOR promotes a multidisciplinary approach to research from different perspectives (biochemical, molecular, epidemiological, clinical, and genetic) that enriches the study of multifactorial processes such as cardiovascular disease.

The group’s research lines focus on descriptive and clinical epidemiology with follow-up of the incidence of AMI and classic risk factors. They have analysed prognostic factors and the incidence of AMI, including biochemical and epigenetic markers, as well as cardiovascular risk, with the development and improvement of cardiovascular risk functions adapted to our environment.

Research group

Members

Irene Román Dégano (Researcher)

Silvia Pérez Fernández (Technician)

Pau Raduà Roy (Technician)

Sussanna Tello Rovira (Technician)

Joan Salvador Vila Domènech (Technician)

Sandra Farré Anton (Research Assistant)

Yolanda Ferrer Campo (Research Assistant)

Sonia Gaixas Vasallo (Research Assistant)

Main PublicationsOngoing Research ProjectsParticipation in Research NetworksClinical Trials Signed in 2019AwardsAppointmentsOutreach

Main Publications

• Hernáez Á, Zomeño MD, Dégano IR, Pérez-Fernández S, Goday A, Vila JS, Civeira F, Moure R, Marrugat J. Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud. Rev Esp Cardiol 2019; 72(11): 916-924. IF 5.126. Q1.

• Subirana I, Fernández-Avilés F, Elosua R, Lidón RM, García-Dorado D, Marrugat J, investigadores del estudio ATHOS. Variabilidad interhospitalaria del tratamiento del síndrome coronario agudo en el estudio ATHOS. Rev Esp Cardiol 2019; 72(8): 691-693. IF 5.126. Q1.

• Sayols-Baixeras S, Fernández-Sanlés A, Prats A, Subirana I, Plusquin M, Künzli N, Marrugat J, Basagaña X, Elosua R. Association between long-term air pollution exposure and DNA methylation: The REGICOR study. Environ Res 2019; 176: 108550. IF 5.026. Q1.

• De Gonzalo D, Elosua R, Vea A, Subirana I, Sayols-Baixeras S, Marrugat J, Llorente-Cortés V. Soluble low-density lipoprotein receptor-related protein 1 as a biomarker of coronary risk: Predictive capacity and association with clinical events. Atherosclerosis 2019; 287: 93-99. IF 4.255. Q2.

• García-Gil M, Comas-Cufí M, Ramos R, Martí R, Alves-Cabratosa L, Parramon D, Prieto-Alhambra D, Baena-Díez JM, Salvador-González B, Elosua R, Dégano IR, Marrugat J, Grau M. Effectiveness of Statins as Primary Prevention in People With Gout: A Population-Based Cohort Study. J Cardiovasc Pharmacol Ther 2019; 24(6): 542-550. IF 2.57. Q2.

See all Publications

Ongoing Research Projects

• Role of micro RNAs expressed by human endothelial and vascular smooth muscle cells in myocardial infarction. (MIRMID: micro RNAs in Myocardial Infarction Disease)

- Financing institution: Fundación BBVA (PR-16_BIO_CAR_0041)

- Period: from 2016 to 2019